Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 2, 2026, BioCryst Pharmaceuticals, Inc. (BCRX) has a Wall Street consensus price target of $14.40, based on estimates from 29 covering analysts. With the stock currently trading at $8.75, this represents a potential upside of +64.6%. The company has a market capitalization of $1.86B.
Analyst price targets range from a low of $8.00 to a high of $25.00, representing a 118% spread in expectations. The median target of $15.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 25 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, BCRX trades at a trailing P/E of 7.2x and forward P/E of 28.1x. Analysts expect EPS to grow -74.1% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $20.32, with bear and bull scenarios of $-1434.69 and $176.64 respectively. Model confidence stands at 28/100, suggesting limited visibility into future performance.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how BCRX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for BCRX is $14.4, representing 64.6% upside from the current price of $8.75. With 29 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
BCRX has a consensus rating of "Buy" based on 29 Wall Street analysts. The rating breakdown is predominantly bullish, with 25 Buy/Strong Buy ratings. The consensus 12-month price target of $14.4 implies 64.6% upside from current levels.
BCRX trades at a forward P/E of 28.1079x, representing a moderate valuation. With analysts targeting $14.4 (64.6% implied move), the stock appears reasonably valued with upside.
The most bullish Wall Street analyst has a price target of $25 for BCRX, while the most conservative target is $8. The consensus of $14.4 represents the median expectation. Our quantitative valuation model projects a bull case target of $177 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
BCRX is heavily covered by Wall Street, with 29 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 25 have Buy ratings, 4 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month BCRX stock forecast based on 29 Wall Street analysts shows a consensus price target of $14.4, with estimates ranging from $8 (bear case) to $25 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $20, with bear/bull scenarios of $-1435/$177.
Our quantitative valuation model calculates BCRX's fair value at $20 (base case), with a bear case of $-1435 and bull case of $177. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 28/100.
BCRX trades at a forward P/E ratio of 28.1x based on next-twelve-months earnings estimates compared to a trailing P/E of 7.2x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on BCRX, with a "Buy" consensus rating and $14.4 price target (64.6% upside). 25 of 29 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
BCRX analyst price targets range from $8 to $25, a 118% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $14.4 consensus represents the middle ground. Our model's $-1435-$177 range provides an independent fundamental perspective.